Micro
Developing
Active
JNJ wins robotic surgery approval
Gaining traction — growing article coverage and momentum.
Score
0.5
Velocity
▲ 2.0
Articles
3
Sources
2
Sentiment Timeline
Event Timeline
🤖
AI Overview
On July 22, Johnson & Johnson (JNJ) received FDA De Novo authorization for its Ottava robotic surgical platform, marking its entry into soft-tissue surgery and directly challenging Intuitive Surgical (ISRG).
This approval drove Intuitive Surgical's stock down, as investors reacted to increased competition in the robotic surgery market. JNJ's Ottava, priced at $1.8 million, undercuts ISRG's da Vinci system, which costs around $2 million. This could pressure ISRG's market share and margins, as hospitals may opt for the more affordable option.
Looking ahead, investors should monitor ISRG's Q2 earnings, due August 3, for any impact on guidance or revenue growth. Additionally, watch for further FDA approvals or regulatory setbacks for JNJ's Ottava, which could shape the competitive landscape in robotic surgery.
This approval drove Intuitive Surgical's stock down, as investors reacted to increased competition in the robotic surgery market. JNJ's Ottava, priced at $1.8 million, undercuts ISRG's da Vinci system, which costs around $2 million. This could pressure ISRG's market share and margins, as hospitals may opt for the more affordable option.
Looking ahead, investors should monitor ISRG's Q2 earnings, due August 3, for any impact on guidance or revenue growth. Additionally, watch for further FDA approvals or regulatory setbacks for JNJ's Ottava, which could shape the competitive landscape in robotic surgery.
AI Overview as of Jul 25, 2026
Timeline
Last UpdatedJul 22, 2026